ELIMINATE-FOG: External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait

Sponsor
The Cleveland Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT05608915
Collaborator
American Parkinson's Disease Association, Inc (Other)
36
1
1
9.4
3.8

Study Details

Study Description

Brief Summary

Postural instability, freezing-of-gait (FOG), and falls are among the greatest unmet needs in Parkinson disease (PD). FOG eventually affects more than half of people with PD, and is notoriously difficult to treat pharmacologically or via deep brain stimulation. Visual cues do improve gait freezing, but their efficacy and adoption is limited because they are not practical to use in all real-world situations. There is a need for a cueing technique that is on-demand and discreet - only perceptible to the patient. Fortunately, recent technological advances in augmented-reality (AR) enable such an approach. In this study, state-of-the-art AR glasses will be used to project digital cues that are only visible to the wearer, to determine if they can improve FOG. 36 individuals with PD and FOG will be recruited to perform an obstacle-course gait task under six cue conditions: no cue, conventional cue, constant-on AR, patient-hand-triggered AR (turns on when patient clicks button), patient-eye-triggered AR (turns on when looking down), and examiner-triggered AR. The AR cue is a set of images that appear on the floor at a patient's feet, mimicking floor lines. Gait performance will be captured on video and via body-worn wireless sensors that detect how each limb is moving. The investigators will determine whether individuals are cue-able with conventional visual cues, whether intermittent cues outperform constant-on cues, and whether cues triggered by an examiner outperform cues triggered by patients themselves.

Condition or Disease Intervention/Treatment Phase
  • Other: No Cue
  • Other: Conventional Cue
  • Other: Constant Cue
  • Other: Patient hand-triggered
  • Other: Patient eye-triggered
  • Other: Examiner-triggered
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
All participants will receive all interventions in a crossover fashion, on the same day. All participants will first experience the conventional cue intervention. The order of the remaining interventions will be randomized. All conditions will be performed after participants hold (do not take) their morning dopaminergic medications.All participants will receive all interventions in a crossover fashion, on the same day. All participants will first experience the conventional cue intervention. The order of the remaining interventions will be randomized. All conditions will be performed after participants hold (do not take) their morning dopaminergic medications.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait
Actual Study Start Date :
Nov 17, 2022
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Augmented-Reality Visual Cues

In this single-arm study, all participants will receive all interventions on the same day. They will be wearing an augmented-reality headset that will display a digital obstacle course. Walking performance will be captured with no visual cues, with conventional visual cues, and with augmented-reality visual cues.

Other: No Cue
There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).

Other: Conventional Cue
Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).

Other: Constant Cue
The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).

Other: Patient hand-triggered
The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).

Other: Patient eye-triggered
The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).

Other: Examiner-triggered
The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).

Outcome Measures

Primary Outcome Measures

  1. Stride Time Coefficient of Variation [For each arm, during the single-day research visit only.]

    Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.

  2. Percent Time Freezing [For each arm, during the single-day research visit only.]

    Marker of gait freezing, derived from video recordings of gait performance, and body-worn wireless sensors.

Secondary Outcome Measures

  1. Step Cadence [For each arm, during the single-day research visit only.]

    Marker of dysfunction, derived from kinematic recordings from body-worn wireless sensors.

  2. Gait Velocity [For each arm, during the single-day research visit only.]

    Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.

  3. Mean Stride Length [For each arm, during the single-day research visit only.]

    Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.

  4. Total Distance Walked [For each arm, during the single-day research visit only.]

    Marker of gait dysfunction, derived from augmented-reality headset and other body-worn wireless sensors

  5. Freezing Index [For each arm, during the single-day research visit only.]

    Marker of gait freezing, derived from kinematic recordings from body-worn wireless sensors.

  6. Number of Freeze Episodes [For each arm, during the single-day research visit only.]

    Marker of gait freezing, derived from video recordings of gait performance, and body-worn wireless sensors.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of PD

  • Presence of freezing of gait, defined as a score of ≥1 in MDS-UPDRS 2.13, or 3.11.

  • Can walk without assistance, OFF meds, based on yes/no verbal response

Exclusion Criteria:
  • Severity of gait impairment should not require dependency to walker or cane

  • Concomitant conditions that may affect significantly the evaluation of balance or gait, including orthopedic, rheumatologic or other neurological diseases

  • Contraindication to physical therapy

  • Severe bilateral visual impairment

  • Age < 21

  • Diagnosis of dementia

  • Not agreeable to having video taken of entire research visit

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cleveland Clinic Foundation Cleveland Ohio United States 44195

Sponsors and Collaborators

  • The Cleveland Clinic
  • American Parkinson's Disease Association, Inc

Investigators

  • Principal Investigator: James Liao, MD PhD, The Cleveland Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT05608915
Other Study ID Numbers:
  • 22-846
First Posted:
Nov 8, 2022
Last Update Posted:
Dec 13, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Cleveland Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 13, 2022